Table 1. Baseline characteristics... | American Society of Hematology

Table 1.

Baseline characteristics

Characteristic	Participant
Characteristic	1	2	3
Age, y	43	50	47
Weight, kg	89	81	82
HIV status	Negative	Positive, controlled	Positive, controlled
Hep B/Hep C	Hep B negative	Hep B negative	Hep B negative
Hep B/Hep C	Hep C; resolved	Hep C; resolved	Hep C; resolved
Hemophilia B status	FIX = 1%	FIX <1%	FIX <1%
Prescreening FIX regimen	Prophylaxis (EHL FIX)	Prophylaxis (EHL FIX)	Prophylaxis (EHL FIX)
Annualized bleed rate 1 y before screening*	3	1	5
NAb titer (AAV5) (luciferase assay)†	Positive	Positive	Positive
NAb titer (AAV5) (luciferase assay)†	48	44	25

Characteristic	Participant
Characteristic	1	2	3
Age, y	43	50	47
Weight, kg	89	81	82
HIV status	Negative	Positive, controlled	Positive, controlled
Hep B/Hep C	Hep B negative	Hep B negative	Hep B negative
Hep B/Hep C	Hep C; resolved	Hep C; resolved	Hep C; resolved
Hemophilia B status	FIX = 1%	FIX <1%	FIX <1%
Prescreening FIX regimen	Prophylaxis (EHL FIX)	Prophylaxis (EHL FIX)	Prophylaxis (EHL FIX)
Annualized bleed rate 1 y before screening*	3	1	5
NAb titer (AAV5) (luciferase assay)†	Positive	Positive	Positive
NAb titer (AAV5) (luciferase assay)†	48	44	25

EHL, extended half-life; Hep, hepatitis.

Total bleeds (treated + untreated).

AAV5 NAb is considered positive if titer is ≥2.¹⁵